Forest earnings drop on higher costs

Forest Laboratories ($FRX) posted a drop in fiscal second-quarter earnings on higher costs, but sales rose 9%, thanks to strong early sales of two new products. But revenue still depends heavily on two older products, Lexapro and Namenda, that are on the verge of losing patent protection, and analysts wonder whether Forest's new drugs are novel enough to capture sizable market share. Report | News

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.